 Leukemia, Myeloid, Acute
"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Descriptor ID |
D015470
|
| MeSH Number(s) |
C04.557.337.539.550
|
| Concept/Terms |
Leukemia, Myeloid, Acute- Leukemia, Myeloid, Acute
- ANLL
- Leukemia, Myeloblastic, Acute
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Acute
- Nonlymphocytic Leukemia, Acute
- Acute Nonlymphocytic Leukemia
- Acute Nonlymphocytic Leukemias
- Leukemia, Acute Nonlymphocytic
- Leukemias, Acute Nonlymphocytic
- Nonlymphocytic Leukemias, Acute
- Leukemia, Nonlymphocytic, Acute
- Myeloblastic Leukemia, Acute
- Acute Myeloblastic Leukemia
- Acute Myeloblastic Leukemias
- Leukemia, Acute Myeloblastic
- Leukemias, Acute Myeloblastic
- Myeloblastic Leukemias, Acute
- Myelocytic Leukemia, Acute
- Acute Myelocytic Leukemia
- Acute Myelocytic Leukemias
- Leukemia, Acute Myelocytic
- Leukemias, Acute Myelocytic
- Myelocytic Leukemias, Acute
- Myelogenous Leukemia, Acute
- Acute Myelogenous Leukemia
- Acute Myelogenous Leukemias
- Leukemia, Acute Myelogenous
- Leukemias, Acute Myelogenous
- Myelogenous Leukemias, Acute
- Myeloid Leukemia, Acute
- Nonlymphoblastic Leukemia, Acute
- Acute Nonlymphoblastic Leukemia
- Acute Nonlymphoblastic Leukemias
- Leukemia, Acute Nonlymphoblastic
- Leukemias, Acute Nonlymphoblastic
- Nonlymphoblastic Leukemias, Acute
- Acute Myeloid Leukemia
- Acute Myeloid Leukemias
- Leukemia, Acute Myeloid
- Leukemias, Acute Myeloid
- Myeloid Leukemias, Acute
- Leukemia, Nonlymphoblastic, Acute
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".
- Leukemia, Myeloid, Acute
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Erythroblastic, Acute
- Leukemia, Mast-Cell
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Promyelocytic, Acute
This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 1 | 4 | | 1981 | 1 | 3 | 4 | | 1982 | 0 | 2 | 2 | | 1983 | 2 | 0 | 2 | | 1984 | 2 | 0 | 2 | | 1986 | 2 | 0 | 2 | | 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 6 | 0 | 6 | | 1990 | 2 | 0 | 2 | | 1991 | 4 | 1 | 5 | | 1992 | 4 | 0 | 4 | | 1993 | 9 | 1 | 10 | | 1994 | 4 | 1 | 5 | | 1995 | 3 | 2 | 5 | | 1996 | 2 | 2 | 4 | | 1997 | 2 | 2 | 4 | | 1998 | 3 | 1 | 4 | | 1999 | 2 | 1 | 3 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 0 | 4 | | 2002 | 7 | 2 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 4 | 1 | 5 | | 2005 | 6 | 0 | 6 | | 2006 | 7 | 1 | 8 | | 2007 | 8 | 1 | 9 | | 2008 | 17 | 0 | 17 | | 2009 | 17 | 0 | 17 | | 2010 | 16 | 1 | 17 | | 2011 | 15 | 2 | 17 | | 2012 | 23 | 1 | 24 | | 2013 | 24 | 1 | 25 | | 2014 | 22 | 0 | 22 | | 2015 | 28 | 0 | 28 | | 2016 | 20 | 3 | 23 | | 2017 | 14 | 5 | 19 | | 2018 | 18 | 2 | 20 | | 2019 | 17 | 1 | 18 | | 2020 | 5 | 0 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
-
Hsu J, Van Besien K, Baron F. Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534.
-
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
-
Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA, Borthakur G, Cantu MD, Margolskee EM, Philip JKS, Sukhanova M, Bagg A, Bueso-Ramos CE, Orazi A, Arber DA, Hsi ED, Hasserjian RP. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 07; 95(7):799-808.
-
Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020 01 30; 135(5):371-380.
-
Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, Bender R, Keeler L, Graber A, Heuck C, Fletcher FA, Alapat D, Weinhold N, Johnson SK, Wickrema A, Barlogie B, Morgan GJ, Shastri A, Steidl U, Will B, Verma A. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019 12 10; 3(23):3962-3967.
-
Ritterhouse LL, Parilla M, Zhen CJ, Wurst MN, Puranik R, Henderson CM, Joudeh NZ, Hartley MJ, Haridas R, Wanjari P, Furtado LV, Kadri S, Segal JP. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Mol Diagn Ther. 2019 12; 23(6):791-802.
-
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
-
Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
-
Brown AL, Hahn C, Hiwase D, Godley LA, Scott HS. Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leuk Lymphoma. 2020 01; 61(1):246-247.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|